Freedom Capital Markets Rates Inspire Medical Systems (INSP) buy

Freedom Capital Markets maintains its positive outlook on Inspire Medical Systems with a $62 price target, a 38.98% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 5:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Freedom Capital Markets rated Inspire Medical Systems, Inc. ($INSP) "buy" with a $62 price target on July 1, 2026.

Since the rating, $INSP is up 8.4% after 1 week, up 10.4% after 1 month and up 51.3% to date (from the $45.46 close on Jul 1, 2026).

INSP Inspire Medical Systems, Inc.

$68.79 -25.45% year to date

Daily close · Oct 16, 2026

Key Points

Freedom Capital Markets reiterated its buy rating on Inspire Medical Systems with a $62 target on July 1, 2026.
Freedom Capital Markets's $62 price target implies 38.98% upside from Inspire Medical Systems, Inc.'s ($INSP) current $44.61 share price.
Shares of Inspire Medical Systems traded near $44.61 on Wednesday, with a market cap of about $1.29 billion and a P/E ratio of 10.14.
Recent insider activity includes sales by John Rondoni and Shawn McCormick, while analysts have varied ratings with a consensus hold recommendation.

Get $INSP trade alerts by text

We text you when insiders, Congress or big funds trade $INSP. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Inspire Medical Systems, Inc. alert may contain errors. Disclosures

Freedom Capital Markets has reiterated its buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) with a price target of $62. This update was made on July 1, 2026, by analyst Keith Hinton.

Inspire Medical Systems, Inc. Stock Down 41.9%

Shares of NYSE:INSP traded near $44.61 on Wednesday. Inspire Medical Systems has a market cap of approximately $1.29 billion and a P/E ratio of 10.14. The stock's 52-week range is between $38.91 and $147.03, with a 50-day moving average of $45.79 and a 200-day moving average of $71.98. The company maintains a strong current ratio of 6.34 and a quick ratio of 4.35.

12-month forecast

$INSP price target

Inspire Medical Systems, Inc. daily closes and this analyst's $62 target. Not advice.

Recent Earnings

In its latest earnings report, Inspire Medical Systems posted revenue of $915.25 million, reflecting a modest growth of 1.6%. The company's net margin stands at 14.33%, with a return on equity of 18.37%. The next earnings release is scheduled for August 3, 2026.

Insider Buying and Selling at Inspire Medical Systems, Inc.

There has been notable insider activity at Inspire Medical Systems. John Rondoni, Chief Product and Innovation Officer, sold 2,641 shares at an average price of $43.28 on May 15, 2026. Earlier, on May 14, he sold 700 shares at $43.01. On May 8, Shawn McCormick sold 696 shares at $45.31 as part of a planned transaction.

Analysts Set New Price Targets

On July 1, 2026, Freedom Capital Markets reiterated a buy rating for Inspire Medical Systems with a $62 price target. Evercore ISI Group downgraded the stock to hold with a $40 target on June 23, 2026. On May 5, 2026, JP Morgan maintained its hold rating with a $54 target, while Piper Sandler also downgraded to hold with a $55 target. The consensus among analysts is a hold rating, with an average target price of $50.92 based on 12 opinions.

About Inspire Medical Systems

Inspire Medical Systems, Inc. is a healthcare company based in Golden Valley, Minnesota. It specializes in developing minimally invasive solutions for obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, uses neurostimulation technology to treat moderate to severe OSA. Founded in 2007, Inspire Medical Systems continues to innovate in the medical devices industry under the leadership of CEO Timothy P. Herbert.

Bottom Line

Inspire Medical Systems remains a company of interest with its innovative approach to treating sleep apnea. The reiterated buy rating from Freedom Capital Markets suggests confidence in its future prospects. However, investors should note that analyst opinions vary, with a consensus hold rating reflecting mixed views on the stock's potential.